GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Active:	No
Cancer Type:	Lung Cancer	NCT ID:	NCT04601402
Trial Phases:	Phase I	Protocol IDs:	[GNC] GEN001-101 (primary) NCI-2020-09143
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Genome & Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT04601402

Summary

This is a phase I/Ib, first-in-human (FIH), open-label, dose escalation and dose
expansion study to evaluate the safety and tolerability, biological and clinical
activities of GEN-001 in patients with locally advanced or metastatic solid tumors who
have progressed on at least two lines of approved therapy for their histological subtypes
which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination), when
administered as combined with avelumab.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.